⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NTLA News
Intellia Therapeutics, Inc
Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
NVO
PFE
CSL
SNY
BMRN
ALNY
SANG
BE
REGN
NTLA
JNJ
ABBV
BMY
TEO
VRTX
CRSP
Intellia Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
NTLA
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
NTLA
Form 8-K
sec.gov
NTLA
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
globenewswire.com
NTLA
Intellia Announces Proposed Public Offering of Common Stock
globenewswire.com
NTLA
Form 8-K
sec.gov
NTLA
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
globenewswire.com
NTLA
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
globenewswire.com
NTLA
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
globenewswire.com
NTLA